Valuation: 4DMedical Limited

Market Cap 2.45B 1.71B 1.52B 1.42B 1.29B 2.43B 164B 17.14B 6.67B 83.87B 6.41B 6.27B 270B P/E 2027 *
-62.5x
P/E 2028 * -150x
Enterprise Value 2.22B 1.55B 1.38B 1.29B 1.17B 2.21B 149B 15.56B 6.05B 76.14B 5.82B 5.69B 245B EV / Sales 2027 *
107x
EV / Sales 2028 * 40.7x
Free-Float
83.97%
Yield 2027 *
-
Yield 2028 * -
1 day+9.09%
1 week+9.09%
Current month+9.09%
1 month+15.38%
3 months+7.14%
6 months-5.06%
Current year+27.66%
1 week 3
Extreme 3
3
1 month 2.47
Extreme 2.47
3
Current year 2.19
Extreme 2.19
5
1 year 0.87
Extreme 0.8701
5
3 years 0.16
Extreme 0.16245
5
5 years 0.16
Extreme 0.16245
5
10 years 0.16
Extreme 0.16245
5
Manager TitleAgeSince
Chief Executive Officer - 2012-11-30
Director of Finance/CFO - 2026-01-01
Chief Tech/Sci/R&D Officer - 2023-03-31
Director TitleAgeSince
Director/Board Member - 2012-11-30
Chairman - 2023-11-01
Director/Board Member - 2017-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+9.09%+9.09% - - 1.71B
+3.35%-0.27%+24.56%+35.89% 250B
+3.34%-2.69%+2.89%+2.00% 156B
+3.71%-2.00%-10.14%+40.12% 144B
-0.47%-3.88%-56.43%-17.96% 61.45B
+2.44%+0.46%+13.18%+20.82% 50.28B
+1.38%-1.84%-21.48%-20.03% 46.73B
+2.09%-2.24%+20.93%+55.22% 48.29B
+3.70%+1.25%-4.33%+40.74% 45.89B
+3.51%-0.64%+34.02%+65.46% 43.24B
Average +3.21%-2.32%+0.36%+24.70% 93.91B
Weighted average by Cap. +2.94%-2.77%+4.28%+25.35%

Financials

2027 *2028 *
Net sales 20.85M 14.53M 12.96M 12.08M 10.99M 20.7M 1.4B 146M 56.78M 714M 54.56M 53.38M 2.3B 55.1M 38.4M 34.26M 31.92M 29.05M 54.7M 3.7B 386M 150M 1.89B 144M 141M 6.07B
Net income -41.1M -28.64M -25.55M -23.8M -21.66M -40.79M -2.76B -288M -112M -1.41B -108M -105M -4.53B -16.65M -11.61M -10.35M -9.65M -8.78M -16.53M -1.12B -117M -45.35M -570M -43.57M -42.63M -1.83B
Net Debt -226M -157M -140M -131M -119M -224M -15.14B -1.58B -614M -7.73B -590M -577M -24.84B -205M -143M -127M -119M -108M -203M -13.74B -1.43B -557M -7.01B -536M -524M -22.54B
Logo 4DMedical Limited
4DMedical Limited is a medical technology company that creates and deploys software-based cardiothoracic imaging technology integrating both algorithms and artificial intelligence. The Company's software platform delivers quantitative insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease. It provides thoracic imaging that enhances physician diagnoses and management of respiratory conditions. Its products include CT:VQ-Non-Contrast Ventilation-Perfusion, CAC-Coronary Artery Calcification, CT LVAS-Lung Ventilation Analysis, IQ-UIP-Early IPF Detection, LDAf-Functional Lung Density Analysis, LDAi-Lung Density Analysis – Inspiration, LTA-Lung Texture Analysis, PHA-Pulmonary Hypertension Assessment, XV LVAS-Lung Ventilation Analysis, and Companion Imaging. The CT:VQ is a non-contrast post-processing technology that transforms routine, chest computed tomographies (CTs) into quantitative, lobar ventilation (V) and perfusion (Q) maps.
Employees
181
Date Price Change Volume
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
4.070AUD
Average target price
4.367AUD
Spread / Average Target
+7.29%

Quarterly revenue - Rate of surprise